Cytarabine syndrome

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Consequences of a therapy with the synthetic pyrimidine nucleoside cytarabine. Cytarabine differs from the physiological nucleosides cytidine and deoxycytidine only in the sugar content: instead of ribose or deoxyribose, arabinose occurs in the cytarabine molecule. Cytarabine is a pyrimidine antagonist.

Clinical featuresThis section has been translated automatically.

The cytarabin syndrome manifests itself through fever, muscle and bone pain, and occasionally chest pain. Other symptoms: maculopapular exanthema, conjunctivitis and general feeling of illness. Cytarabine syndrome and usually occurs 6-12 hours after administration of the drug.

TherapyThis section has been translated automatically.

For treatment or prophylaxis, the administration of corticosteroids has proven to be helpful. If the symptoms are considered treatable, the combined use of corticosteroids should be considered with continued therapy.

LiteratureThis section has been translated automatically.

  1. Berg I et al (2013) Rash and ear swelling in a patient with febrile neutropenia. Int J Infect Dis 17:e360-e361.
  2. Cetkovská P et al (2002) High-dose cytosine arabinoside-induced cutaneous reactions.J Eur Acad Dermatol Venereol16:481-485.
  3. Ruben BS et al (2015) Generalized benign cutaneous reaction to cytarabine. J Am Acad Dermatol 73:821-828.

Authors

Last updated on: 29.10.2020